JP2009502974A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009502974A5 JP2009502974A5 JP2008524308A JP2008524308A JP2009502974A5 JP 2009502974 A5 JP2009502974 A5 JP 2009502974A5 JP 2008524308 A JP2008524308 A JP 2008524308A JP 2008524308 A JP2008524308 A JP 2008524308A JP 2009502974 A5 JP2009502974 A5 JP 2009502974A5
- Authority
- JP
- Japan
- Prior art keywords
- mutilin
- acetyl
- sulfanyl
- cyclopent
- ethylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960002771 retapamulin Drugs 0.000 claims description 40
- -1 (3- (morpholin-4-yl) -cyclohexane-1-yl) -sulfanyl Chemical group 0.000 claims description 35
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- OBUUFWIMEGVAQS-UHFFFAOYSA-N Pleuromutenol Natural products CC1C(O)C(C)(C=C)CC(O)C2(C)C(C)CCC31C2C(=O)CC3 OBUUFWIMEGVAQS-UHFFFAOYSA-N 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- STZYTFJPGGDRJD-NHUWBDDWSA-N retapamulin Chemical compound C([C@H]([C@@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]2C)OC(=O)CS[C@@H]3C[C@H]4CC[C@H](N4C)C3)C)C[C@]32[C@H]1C(=O)CC3 STZYTFJPGGDRJD-NHUWBDDWSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000001301 oxygen Chemical group 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000005322 morpholin-1-yl group Chemical group 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0515995.9 | 2005-08-03 | ||
| GBGB0515995.9A GB0515995D0 (en) | 2005-08-03 | 2005-08-03 | Organic compounds |
| PCT/AT2006/000318 WO2007014409A1 (en) | 2005-08-03 | 2006-07-26 | Pleuromutilin derivatives useful as antibacterials |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009502974A JP2009502974A (ja) | 2009-01-29 |
| JP2009502974A5 true JP2009502974A5 (enExample) | 2012-12-13 |
| JP5372505B2 JP5372505B2 (ja) | 2013-12-18 |
Family
ID=34984042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008524308A Expired - Fee Related JP5372505B2 (ja) | 2005-08-03 | 2006-07-26 | 抗菌活性を示すプレウロムチリン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8343972B2 (enExample) |
| EP (2) | EP1910282B1 (enExample) |
| JP (1) | JP5372505B2 (enExample) |
| GB (1) | GB0515995D0 (enExample) |
| TW (1) | TWI414511B (enExample) |
| WO (1) | WO2007014409A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1808431A1 (en) * | 2006-01-16 | 2007-07-18 | Nabriva Therapeutics Forschungs GmbH | Mutilin derivatives and their use as pharmaceutical |
| EP1972618A1 (en) * | 2007-03-20 | 2008-09-24 | Nabriva Therapeutics AG | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
| JP5322927B2 (ja) | 2007-05-24 | 2013-10-23 | 杏林製薬株式会社 | １４位置換基に複素芳香環カルボン酸構造を有するムチリン誘導体 |
| EP2159220A1 (en) * | 2008-09-02 | 2010-03-03 | Nabriva Therapeutics AG | Organic compounds |
| US20100184987A1 (en) * | 2008-11-13 | 2010-07-22 | Teva Pharmaceutical Industries Ltd. | Preparation of Retapamulin via its Pleuromutilin-thiol precursor |
| EP2433926A1 (en) | 2010-09-09 | 2012-03-28 | Nabriva Therapeutics AG | Pleuromutilin derivatives for use in the treatment of diseases mediated by microbes |
| CN103204787B (zh) * | 2012-01-17 | 2014-10-01 | 北京艾百诺科技有限公司 | 含有取代方酸的乙酸妙林酯及其应用 |
| US11155772B2 (en) * | 2012-03-20 | 2021-10-26 | Firmenich Sa | Compounds for a controlled release of active perfuming molecules |
| CN103319437B (zh) * | 2013-06-20 | 2016-05-04 | 中国农业科学院兰州畜牧与兽药研究所 | 具有噻二唑骨架的截短侧耳素类衍生物及其制备方法、应用 |
| PT3310331T (pt) | 2015-06-17 | 2021-01-19 | Nabriva Therapeutics GmbH | Formulações farmacêuticas injetáveis de lefamulina |
| TWI762573B (zh) | 2017-02-10 | 2022-05-01 | 奧地利商納畢瓦治療有限責任公司 | 截短側耳素之純化 |
| CN113631548B (zh) | 2019-03-28 | 2023-06-06 | 硕腾服务有限责任公司 | 血清素5-ht2b抑制化合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9918037D0 (en) * | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| GB0017031D0 (en) * | 2000-07-11 | 2000-08-30 | Biochemie Gmbh | Antimicrobials |
| GB0207495D0 (en) | 2002-03-28 | 2002-05-08 | Biochemie Gmbh | Organic compounds |
| GB0209262D0 (en) * | 2002-04-23 | 2002-06-05 | Biochemie Gmbh | Organic compounds |
| DE60317208T2 (de) * | 2002-07-24 | 2008-08-07 | Nabriva Therapeutics Forschungs Gmbh | Pleuromutilinderivate als antimikrobielle mittel |
| GB0308114D0 (en) * | 2003-04-08 | 2003-05-14 | Glaxo Group Ltd | Novel compounds |
-
2005
- 2005-08-03 GB GBGB0515995.9A patent/GB0515995D0/en not_active Ceased
-
2006
- 2006-07-26 EP EP06760805.9A patent/EP1910282B1/en not_active Expired - Lifetime
- 2006-07-26 JP JP2008524308A patent/JP5372505B2/ja not_active Expired - Fee Related
- 2006-07-26 US US11/997,637 patent/US8343972B2/en not_active Expired - Fee Related
- 2006-07-26 EP EP10009686A patent/EP2266956A3/en not_active Withdrawn
- 2006-07-26 WO PCT/AT2006/000318 patent/WO2007014409A1/en not_active Ceased
- 2006-08-02 TW TW095128307A patent/TWI414511B/zh not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102544847B1 (ko) | 4Ｈ-피롤로［3,2-ｃ］피리딘-4-온 유도체 | |
| RU2497807C2 (ru) | Карбазольные соединения и терапевтические применения соединений | |
| US12558356B2 (en) | Immunophilin binding agents and uses thereof | |
| JP2019524883A5 (enExample) | ||
| JP2017514830A5 (enExample) | ||
| JP2020505395A5 (enExample) | ||
| NO20056007L (no) | Dobbel NK1/NK3 antagonister for behandling av schizofreni | |
| JP2017525668A5 (enExample) | ||
| WO2005087729A1 (en) | 5-hydroxyindole-3-carboxylates derivatives and their use | |
| JP2005510473A5 (enExample) | ||
| RU2008110941A (ru) | ИНГИБИТОРЫ КИНАЗЫ p38 МАР И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| RU2007120454A (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| RU2354655C2 (ru) | Ингибиторы сомт | |
| RU2013147744A (ru) | Дозированная лекарственная форма для перорального применения | |
| JP2006501201A5 (enExample) | ||
| JP2015505301A5 (enExample) | ||
| CY1112086T1 (el) | Συνδυασμος γλυκοπυρρολικου αλατος και ενος αγωνιστη βητα2 αδρενεργικων υποδοχεων | |
| JP2013508382A5 (enExample) | ||
| JP2010513322A5 (enExample) | ||
| JP2011526247A5 (enExample) | ||
| JP2018531987A5 (enExample) | ||
| JP2013532709A5 (enExample) | ||
| JP2013529206A5 (enExample) | ||
| JP2010527985A5 (enExample) | ||
| US20180086739A1 (en) | Plk4 inhibitors |